AbbVie is showing that its post-Humira rebuild is real, with Skyrizi and Rinvoq driving strong growth and full-year guidance moving higher. Heavy debt and a negative equity position remain the main risks, but cash flow and earnings power still look compelling.
AbbVie(ABBV) remains a high-quality large-cap biopharma story built on a simple but powerful transition: the company has moved from Humira dependence to a broader growth engine led by Skyrizi and Rinvoq, while neuroscience, aesthetics, and oncology add diversification and cash flow support. In Q1 2026, AbbVie reported $15.002B in revenue, up 12.4%, and adjusted EPS of $2.65, while raising full-year adjusted EPS guidance to $14.08 to $14.28 and full-year revenue guidance to about $67.3B. That combination matters. It shows the post-Humira rebuild is not theoretical anymore. It is showing up in reported numbers.
The core investment case rests on three facts. First, Skyrizi and Rinvoq are now massive franchises. In 2025, Skyrizi generated $17.562B and Rinvoq generated $8.304B, for a combined $25.866B. Second, those assets are still growing quickly. In Q1 2026, Skyrizi rose 30.9% reported to $4.483B and Rinvoq rose 23.3% reported to $2.119B. Third, AbbVie still throws off substantial cash, with 2025 free cash flow of $17.82B and a 5.29% FCF yield. That gives management room to invest in R&D, fund manufacturing expansion, support the dividend, and pursue business development.
The main pushback is also clear. AbbVie carries heavy debt, with $69.07B of total debt and net cash of -$63.81B based on the debt snapshot, while book value per share is negative at -3.767 and equity was -$3.23B at year-end 2025. The market is not wrong to charge a balance-sheet discount for that. Add in Humira erosion, which drove Q1 2026 sales down 40.3% operationally to $688M, and this is not a clean, low-risk compounder.
For a balanced, moderate-risk investor, the stock still looks attractive because the earnings power implied by the forward P/E of 15.2 does not fully reflect the quality of AbbVie’s growth mix, the durability of its immunology franchise, and the depth of its commercial platform. The market is treating AbbVie like a company still trapped in the Humira comedown. The numbers increasingly show a company already on the other side of it.
AbbVie(ABBV) is a research-based biopharmaceutical company headquartered in North Chicago, Illinois, with 57,000 employees and operations spanning immunology, neuroscience, oncology, aesthetics, eye care, and other specialty therapeutics. The company was incorporated in 2012 and began trading in 2013. It sells globally and operates through a broad specialty-medicine model rather than a mass-market primary-care model, which means physician relationships, payer access, specialty pharmacy execution, and lifecycle management all matter more than simple unit volume.
AbbVie reports as a single operating segment, but the business is best understood through its therapeutic portfolios. In 2025, total revenue reached $61.16B. Immunology was the center of gravity, led by Skyrizi at $17.562B, Rinvoq at $8.304B, and Humira at $4.540B. Neuroscience added major scale through Botox Therapeutic at $3.769B, Vraylar at $3.621B, Ubrelvy at $1.271B, and Qulipta at $1.036B. Aesthetics remained meaningful with Botox Cosmetic at $2.602B and Juvederm at $993M. Oncology contributed through Venclexta at $2.792B and Imbruvica at $2.869B.
That mix matters because AbbVie today is no longer a one-drug story. In 2023, Humira still represented 27.2% of revenue. By 2025, that fell to 7.8%, while Skyrizi climbed to 30.2% and Rinvoq to 14.3%. The company has effectively swapped a declining blockbuster for two newer blockbusters with expanding labels and stronger growth. That is the strategic handoff investors needed to see after Humira lost exclusivity.
CEO Robert Michael’s comment is backed by the quarter. Q1 2026 revenue rose 12.4%, adjusted EPS was $2.65, and management lifted full-year guidance. For a company of AbbVie’s size, that is not cosmetic. It is evidence that the portfolio transition is working at scale.
Immunology is the engine room. In Q1 2026, the portfolio generated $7.290B, up 16.4% reported. Skyrizi contributed $4.483B and Rinvoq added $2.119B, while Humira fell to $688M. On a full-year 2025 basis, immunology was even more dominant: Skyrizi and Rinvoq alone represented $25.866B of revenue, or more than 42% of company sales. This is where AbbVie’s growth, margin profile, and strategic identity now sit.
Neuroscience is the second pillar. Q1 2026 neuroscience revenue was $2.875B, up 26.0% reported. Vraylar delivered $905M, Botox Therapeutic reached $1.009B, Ubrelvy and Qulipta combined for $635M, and Vyalev contributed $201M. On a 2025 basis, neuroscience revenue totaled $10.77B. This business gives AbbVie a less cyclical, high-value specialty portfolio outside immunology, with growth spread across psychiatry, migraine, movement disorders, and therapeutic neurotoxins.
Oncology is smaller and more mixed. Q1 2026 oncology revenue was $1.631B, down 0.2% reported and down 3.0% operationally. Venclexta was the bright spot at $770M and up 9.7% operationally, while Imbruvica fell 24.7% due to IRA pricing and competitive share pressure. In plain English, oncology is doing what mature pharma portfolios often do: one asset grows, another fades, and the pipeline has to carry the next leg.
Aesthetics remains a useful cash generator, but it is the least defensive part of the portfolio. Q1 2026 aesthetics revenue was $1.186B, up 7.6% reported. Botox Cosmetic rose to $668M, up 17%, while Juvederm fell to $232M, down 2.9%. In 2025, aesthetics revenue totaled about $4.86B, with Botox Cosmetic at $2.602B and Juvederm at $993M. The business still has brand strength, but it is more exposed to consumer spending and competitive filler dynamics than AbbVie’s prescription franchises.
Eye care, GI, virology, and other legacy products round out the model. Mavyret generated $1.317B in 2025, Linzess/Constella added $907M, Ozurdex contributed $493M, and other eye care products added $1.009B. These are not the headline growth drivers, but they help stabilize the revenue base and support the cash flow machine.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
Skyrizi is AbbVie’s flagship asset and the clearest reason the Humira cliff did not become a business collapse. In 2025, Skyrizi generated $17.562B, up sharply from $11.718B in 2024 and $7.763B in 2023. In Q1 2026, sales reached $4.483B, up 30.9% reported and 29.2% operationally. Management also raised its 2026 Skyrizi revenue outlook to $21.6B. Those are blockbuster numbers in the literal sense, not the Wall Street marketing sense.
The commercial case for Skyrizi is unusually strong because it combines scale, label breadth, and clinical reinforcement. Management highlighted leadership in psoriatic disease, strong uptake in IBD, and new label support in difficult-to-treat psoriasis areas. The company also cited nearly 90% of patients showing no radiographic progression through 5 years of treatment in psoriatic arthritis. That is how a franchise becomes sticky. It is not just a drug. It becomes the physician default.
Rinvoq is the second half of the immunology one-two punch. It generated $8.304B in 2025 after $5.971B in 2024 and $3.969B in 2023. In Q1 2026, revenue reached $2.119B, up 23.3% reported. Management raised its 2026 Rinvoq outlook to $10.2B and pointed to strong demand across indications, especially gastro. Rinvoq also has regulatory expansion in motion, including a recent FDA application in alopecia areata.
Humira still matters, but now mostly as a drag that is becoming easier to absorb. Revenue fell from $14.404B in 2023 to $8.993B in 2024 and then to $4.540B in 2025. In Q1 2026, Humira was down to $688M, down 40.3% operationally. The important point is not that Humira is shrinking. Everyone knew that. The important point is that AbbVie has already built enough replacement revenue to keep total company growth positive.
Outside immunology, Botox remains a franchise rather than a product. Botox Therapeutic generated $3.769B in 2025 and delivered $1.009B in Q1 2026. Botox Cosmetic generated $2.602B in 2025 and $668M in Q1 2026. That dual medical and consumer presence gives AbbVie an unusual brand moat. Few pharma companies own an asset that can sit in both a neurologist’s office and a med-spa with equal pricing power.
Vraylar also deserves attention. It generated $3.621B in 2025 and $905M in Q1 2026, up 18.4%. That is meaningful because psychiatry franchises with durable branded growth are not easy to build. Combined with migraine assets Ubrelvy and Qulipta, Vraylar helps make neuroscience a real second growth platform rather than a side business.
AbbVie’s moat starts with commercial scale and specialist focus. The company operates in disease areas where access, physician familiarity, dosing convenience, and evidence generation matter as much as molecule novelty. That is why Skyrizi and Rinvoq have scaled so quickly. AbbVie is not just selling drugs. It is running a large, disciplined commercialization machine across dermatology, gastroenterology, rheumatology, neurology, psychiatry, oncology, and aesthetics.
The second moat is lifecycle execution. Skyrizi and Rinvoq are not static assets. AbbVie is still expanding them through new data, new settings, and new indications. In the Q1 2026 update, management cited the U.S. regulatory submission of Skyrizi subcutaneous induction in Crohn’s disease and the FDA application for Rinvoq in alopecia areata. It also highlighted additional late-stage programs for Rinvoq in vitiligo, hidradenitis suppurativa, and SLE in pipeline materials.
That line from management would be empty corporate wallpaper if the pipeline were thin. It is not. AbbVie outlined progress in immunology combinations, Parkinson’s disease, obesity, solid tumors, hematologic oncology, migraine, and aesthetics. The Crohn’s platform study combining Skyrizi with ABBV-382 produced approximately 42% endoscopic remission at week 24, with the rate double either monotherapy arm. Early-stage obesity candidate ABBV-295 showed nearly 10% weight loss after 12 weeks in a multiple ascending dose study. Tavapadon remains on track for a third-quarter approval decision in Parkinson’s disease.
The third moat is cash-funded optionality. AbbVie generated $19.03B in operating cash flow and $17.82B in free cash flow in 2025. Management said it has significant financial capacity to pursue early and late-stage opportunities, and the company has already used M&A to deepen neuroscience and oncology through deals such as Cerevel and ImmunoGen, while also citing the Remagen agreement in the Q1 2026 call. This is how large biopharma stays relevant: internal R&D plus external deal flow, with cash doing the heavy lifting.
AbbVie’s operations story is not glamorous, but it is important. Specialty pharma lives and dies by manufacturing reliability, regulatory compliance, and the ability to support biologics, injectables, and complex therapies at scale. Management tied that directly to future growth by announcing several new manufacturing projects as part of a $100B commitment to U.S. R&D and capital investments over the next decade.
Those investments are not small maintenance checks. They are capacity decisions aimed at supporting immunology, neuroscience, oncology, and obesity. For investors, the read-through is twofold. First, AbbVie is signaling confidence in demand durability for its growth franchises. Second, the company is trying to reduce execution risk by controlling more of the production backbone. In biopharma, supply chain strength is like plumbing in a skyscraper: nobody notices it until it fails, and then it is the whole story.
There are still operational risks. In aesthetics, the FDA issued a complete response letter tied to manufacturing questions for a fast-acting short-duration toxin candidate. Management said the CRL did not identify safety, efficacy, or labeling issues and did not request additional clinical trials. That narrows the problem to manufacturing and submission work, but it also shows the usual truth in pharma: even promising assets can get delayed by the factory, not the science.
AbbVie operates across large and growing therapeutic markets. Broader biotechnology market estimates vary widely by scope, but cited industry sources place 2026 market size between roughly $1.5T and $2.4T, with long-term growth in the low-teens to mid-teens. That top-down number is less useful than AbbVie’s actual exposure. The company is concentrated in immunology, neuroscience, oncology, and aesthetics, all of which are large specialty categories with durable demand and premium pricing.
Immunology remains the biggest opportunity. AbbVie’s own numbers show why. Skyrizi and Rinvoq combined for $25.866B in 2025, and management reiterated a 2027 combined sales outlook of more than $31B. That implies several more years of meaningful franchise expansion even after these drugs have already reached mega-blockbuster scale. When a company can still grow its largest assets from a very large base, the market usually pays attention.
Neuroscience also offers a broad runway. In 2025, neuroscience revenue was $10.77B, and Q1 2026 growth was 26.0% reported. Migraine, psychiatry, and Parkinson’s disease all contribute. This matters because it reduces dependence on one therapeutic area and gives AbbVie multiple shots on goal for growth without relying entirely on early-stage science.
Aesthetics is a different market dynamic. It has attractive long-term demand, but it is more cyclical and more exposed to consumer confidence. AbbVie still expects high single-digit CAGR for aesthetics from 2025 through 2029, yet recent product-level results show a split picture: Botox Cosmetic grew strongly in Q1 2026, while Juvederm remained under pressure. That is the kind of market where brand matters, but macro matters too.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
AbbVie’s customers are not a single group. In immunology, oncology, neuroscience, and eye care, the company sells primarily through specialist physicians, hospitals, infusion centers, and specialty pharmacies, with payer access playing a major role in uptake. In aesthetics, the customer base expands to dermatologists, plastic surgeons, med-spas, and cash-pay consumers. That mix gives AbbVie both resilience and complexity.
The physician-facing customer profile favors companies with strong field execution and evidence generation. AbbVie’s management repeatedly highlighted in-play share gains, new patient starts, and label support for Skyrizi and Rinvoq. Those are not vanity metrics. In specialty pharma, they are the leading indicators of future revenue durability because switching costs are clinical, administrative, and behavioral.
The consumer-facing side is more sensitive. Botox Cosmetic and Juvederm depend on procedure demand and discretionary spending. Q1 2026 showed Botox Cosmetic revenue of $668M, up 17%, while Juvederm fell 2.9% to $232M. That split suggests AbbVie’s strongest aesthetics asset still has pricing and brand power, but the broader filler market remains more fragile.
AbbVie competes against a long list of large-cap pharma rivals. In immunology, the main competitors include Johnson & Johnson, Amgen, Pfizer, Bristol Myers Squibb, Novartis, UCB, and Eli Lilly. In neuroscience and migraine, AbbVie faces Eli Lilly, Pfizer, Amgen, Teva, and Biohaven. In aesthetics, it competes with Evolus, Galderma, Merz, and Revance. In oncology, the field includes Roche, Merck, AstraZeneca, Bristol Myers Squibb, Johnson & Johnson, Gilead, and Amgen.
The most important competitive battleground is immunology. AbbVie’s defense there is not just scale, but product positioning. Management said Skyrizi has clear leadership over biologics and orals in psoriatic disease, with strong efficacy, durable response, and quarterly dosing. It also said Skyrizi continues to capture a leading share of total new patient starts in U.S. IBD. That is the kind of language companies use when they believe the market share data is doing the arguing for them.
Rinvoq faces a different competitive setup because oral immunology is crowded and safety perceptions matter. Even so, AbbVie reported strong demand across indications and a prescription inflection in gastro, especially ulcerative colitis, after expanded label support. That suggests Rinvoq is holding its own where convenience and earlier-line use can drive adoption.
The weak spots are visible too. Humira is the obvious one, with biosimilar competition now fully entrenched. Imbruvica is another, with Q1 2026 sales down 24.7% due to IRA pricing and competitive share pressure. AbbVie is winning enough elsewhere to offset those declines, but the portfolio still contains assets that are moving from moat to runoff.
AbbVie sits in a sector with both defensive and policy-sensitive traits. Demand for many of its therapies is medically necessary and recurring, which helps during slower economic periods. That is one reason the stock’s beta is only 0.309. The market sees AbbVie as less volatile than the average equity, and the business mix supports that view.
At the same time, pharma is never insulated from policy. Biosimilar pressure has already reset Humira. In oncology, management specifically cited IRA pricing as a factor behind Imbruvica’s 24.7% decline in Q1 2026. That is a reminder that Washington can hit revenue just as effectively as a competitor can. Drug pricing, reimbursement rules, and international regulatory timelines remain material variables for the whole group.
Foreign exchange also matters, though it helped rather than hurt in Q1 2026. AbbVie said the quarter’s 12.4% revenue growth included a 2.1% favorable impact from FX. For the full year, management still expects FX to remain roughly in line with prior assumptions. This is not the main story, but it does affect reported growth for a global pharma company.
Geopolitically, AbbVie’s announced U.S. manufacturing investments fit a broader industry trend toward supply chain resilience and domestic capacity. In a world where regulators, trade policy, and national industrial strategy increasingly overlap, local production is not just an operational choice. It is a strategic hedge.
$69.07B of total debt and negative equity of -$3.23B leave AbbVie with a clear balance-sheet discount even after strong cash generation.
Unlock the full analysis
Subscribers get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Q1 2026 revenue rose 12.4% to $15.002B and adjusted EPS reached $2.65, showing the earnings base is still expanding.
Unlock the full analysis
Subscribers get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Management lifted 2026 adjusted EPS guidance to $14.08-$14.28 and revenue guidance to about $67.3B, signaling continued momentum.
Unlock the full analysis
Subscribers get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →A forward P/E of 15.2 leaves AbbVie priced below the growth implied by Skyrizi, Rinvoq, and its broader specialty portfolio.
Unlock the full analysis
Subscribers get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →The report’s fair value sits at $255, with the stock still offering upside relative to the current setup if growth and cash flow hold.
Unlock the full analysis
Subscribers get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →AbbVie(ABBV) has done the hard part of the post-Humira transition. It built two giant replacement franchises in Skyrizi and Rinvoq, kept neuroscience growing, preserved strong cash generation, and showed enough pipeline depth to support the next phase of the story. Q1 2026 reinforced that progress with $15.002B in revenue, 12.4% growth, adjusted EPS of $2.65, and higher full-year guidance.
This is not a perfect business. The balance sheet is stretched, negative equity is ugly, and some older assets are in visible decline. But investing is rarely about perfect businesses at cheap prices. More often, it is about deciding whether the market is still anchored to an old narrative after the facts have changed. In AbbVie’s case, the old narrative was Humira dependence. The new facts are a diversified growth portfolio, rising guidance, and a fair value estimate of $255 that still sits above where the stock has recently traded.
For moderate-risk investors with a medium-term horizon, AbbVie remains a Buy. The stock offers a mix of growth, cash flow, and relative defensiveness that is hard to find in one package. It is not flashy. It is just increasingly hard to dismiss.
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.
Get Full Access →
AbbVie Inc. (ABBV) rises after announcing a $10.9 billion all-cash acquisition of Apogee Therapeutics. The deal expands AbbVie’s immunology pipeline and reinforces its post-Humira growth strategy, while strong recent earnings and raised guidance add support to the rally.
The MBA’s 30-year mortgage rate edged down to 6.59%, but borrowing costs remain trapped near 6.6%. Applications rose slightly, yet purchase demand stayed weak while refinancing picked up. The latest data suggest housing is getting only marginal relief, not a meaningful turnaround.
May new home sales fell 7.3%, a sharp miss that underscores how high mortgage rates and stretched affordability are weighing on demand. Building permits also slipped, suggesting builders are becoming more cautious as the housing market continues to lose momentum.